MONOPAR THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.66 USD | +1.54% |
|
+5.18% | +94.00% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.52M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M | Net income 2025 * | -10M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.14
x | P/E ratio 2025 * |
-1.47
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.65% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.54% | ||
| 1 week | +5.18% | ||
| Current month | -0.02% | ||
| 1 month | +3.12% | ||
| 3 months | +81.32% | ||
| 6 months | +28.16% | ||
| Current year | +94.00% |
1 week
0.63
0.69
1 month
0.500.85
Current year
0.311.73
1 year
0.271.75
3 years
0.276.98
5 years
0.2748.00
10 years
0.2748.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 40 | 14-11-30 | |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
Laura Kelly
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brown
BRD | Director/Board Member | 67 | 14-11-30 |
Arthur Klausner
BRD | Director/Board Member | 64 | 17-07-31 |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 0.66 | +1.54% | 32,147 |
| 24-05-01 | 0.65 | -1.53% | 19,680 |
| 24-04-30 | 0.6601 | +1.55% | 54,655 |
| 24-04-29 | 0.65 | -1.25% | 15,062 |
| 24-04-26 | 0.6582 | +4.89% | 35,008 |
Delayed Quote Nasdaq, May 02, 2024 at 04:30 pm EDT
More quotes
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.66
USD
Average target price
3.363
USD
Spread / Average Target
+409.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +94.00% | 11.52M | |
| +26.28% | 48.09B | |
| -3.99% | 40.43B | |
| +45.32% | 40.62B | |
| -6.20% | 28.36B | |
| +6.36% | 24.89B | |
| -21.47% | 19.01B | |
| +27.58% | 12.09B | |
| -2.75% | 11.8B | |
| -2.02% | 11.88B |
- Stock Market
- Equities
- MNPR Stock
